WATERTOWN, Mass. – EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:) has introduced new subgroup analyses from its Phase 2 DAVIO 2 medical trial, which spotlight the potential of EYP-1901 as a therapy for wet age-related macular degeneration (wet AMD (NASDAQ:)). The information, introduced on the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting on Sunday, recommend EYP-1901 may alter the therapy paradigm for sufferers with this retinal illness.
EYP-1901 combines vorolanib, a tyrosine kinase inhibitor, with the bioerodible Durasert E expertise for sustained supply. The subgroup evaluation confirmed numerical superiority in visible acuity and anatomic stability for sufferers handled with EYP-1901 in comparison with these given aflibercept, with out the necessity for supplemental injections as much as six months.
The Phase 2 DAVIO 2 trial met its major endpoint, with EYP-1901 demonstrating statistical non-inferiority in visible acuity modifications and a positive security profile in comparison with aflibercept. Secondary endpoints have been additionally achieved, notably a major discount in therapy burden and powerful anatomical management.
EyePoint CEO Jay Duker, M.D., expressed confidence within the information, affirming that the positive outcomes have been attributable to EYP-1901. The firm plans to provoke Phase 3 trials within the second half of 2024, following discussions with the U.S. Food and Drug Administration (FDA).
Wet AMD is a number one reason for imaginative and prescient loss in people over 60, and present therapies require frequent injections. EYP-1901’s sustained supply may scale back this burden, with the current trial exhibiting as much as 88% therapy burden discount at six months.
EyePoint Pharmaceuticals can be progressing with different medical milestones for EYP-1901, together with a Phase 2 trial in non-proliferative diabetic retinopathy, with topline information anticipated within the second quarter of 2024.
This report relies on a press launch assertion from EyePoint Pharmaceuticals. The firm is devoted to the event and commercialization of therapeutics for severe retinal illnesses. Its pipeline options the proprietary Durasert E expertise for intraocular drug supply. EyePoint’s lead product candidate, EYP-1901, is below investigation for a number of VEGF-mediated retinal illnesses.
This article was generated with the help of AI and reviewed by an editor. For extra data see our T&C.